anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Direct intramuscular or intravenous injection of Cupric Chloride Injection, USP 0.4 mg/mL is contraindicated, as the acidic pH of the solution (2) may cause considerable tissue irritation.

Liver and/or biliary tract dysfunction may require omission or reduction of copper and manganese doses because these elements are primarily eliminated in the bile.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
ABSTRACT        The specification describes novel thiazinobenz-midazole derivatives represented by the general formula:           wherein R1, R2 and X represent a wide variety of substi-tuent groups respectively.  The above thiazinobenzimidazole derivatives may be prepared by reacting corresponding 2-hydroxymethyl thiazinobenzimidazole derivatives with cor-responding reactive derivatives of carboxylic acids or hal-ogenides or by reacting 2-p-toluenesulfonyloxymethyl-thiazino-benzimidazole derivatives with sodium azides, thiols, phenols or amines.  The above thiazinobenzimidazole deriv-atives wherein X is OH may be prepared by reducing their corresponding 2-alkoxycarbonyl derivatives.  Where X re-presents a p-toluenesulfonyloxy group, the thiazinobenz-imidazole derivatives may be obtained by reacting correspond-ing 2-hydroxymethyl-thiazinobenzimidazole derivatives with p-toluenesulfonyl chloride.  Where X stands for an N-sub-stituted 2-(homo)piperazinomethyl group, 2-(homo)piperazino-methyl-thiazinobenzimidazole derivatives are reacted with reactive compounds to introduce the desired substituent groups.  The thiazinobenzimidazole derivatives according to this invention are useful as medicaments for circulatory systems.
Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
BACKGROUND: In Senegalese high-burden regions, the existing package of interventions is insufficient to reach the malaria elimination goal. Asymptomatic carriers of Plasmodium contribute significantly to malaria persistence and are not targeted by current interventions. The systematic treatment of all individuals in a community (mass drug administration, MDA) is a relevant intervention to tackle asymptomatic infections. The intervention can only be effective with a high participation of the population and, therefore, depends largely on its acceptability. This study aims to investigate the prospective acceptability of MDA in the Kedougou region to inform its potential use in a future strategy.
METHODS: Following a 7-construct theoretical framework, prospective acceptability of MDA implemented in the rainy season was studied. In four villages, a sequential mixed design, from qualitative to quantitative, was used. In November 2021, interviews with healthcare professionals and focus groups with villagers were conducted. Findings from thematic analysis informed the development of a questionnaire administered to individuals aged ≥ 15 years in March 2022. Based on the questionnaire, an acceptability score was constructed and associations with socio-demographic factors were investigated using a linear mixed model.
RESULTS: The 7 interviews, the 12 focus groups, and the questionnaire administered to 289 individuals demonstrated a good acceptability of MDA. Two potential barriers were identified: the contradiction of taking a medication without feeling sick and the occurrence of side effects; and four facilitators: the perception of malaria as a burden, a good understanding of MDA, a good perceived effectiveness, and the resulting economic benefits. The average acceptability score was 3.5 (range from -7 to + 7). Young adults aged 15 to 21 had a lower acceptability score compared to the other age groups, indicating an additional barrier to acceptability (β = -0.78 [-1.67;0.1]).
CONCLUSION: MDA is a priori acceptable to communities of Kedougou region in Senegal. Sensitization campaigns co-constructed with the communities, especially targeting young adults, are essential to ensure good acceptability.
The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed "Up and Go" test, Tinetti Balanced Test, Berg Balance Scale.
Of the total number of patients in clinical studies of Lidocaine and Prilocaine Cream, 180 were age 65 to 74 and 138 were 75 and over. No overall differences in safety or efficacy were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Plasma levels of lidocaine and prilocaine in geriatric and non-geriatric patients following application of a thick layer of Lidocaine and Prilocaine Cream are very low and well below potentially toxic levels. However, there are no sufficient data to evaluate quantitative differences in systemic plasma levels of lidocaine and prilocaine between geriatric and non-geriatric patients following application of Lidocaine and Prilocaine Cream.

Consideration should be given for those elderly patients who have enhanced sensitivity to systemic absorption (see PRECAUTIONS).

After intravenous dosing, the elimination half-life of lidocaine is significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours). (See CLINICAL PHARMACOLOGY).
All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
IMPORTANCE: Electrographic seizures (ESz) are seizures without prominent motor activity diagnosed with electroencephalogram and are a common complication in critically ill patients with alterations of consciousness. Previous studies suggested clinical signs, including ocular movement abnormalities, facial/periorbital twitching, or remote seizure risk factors, are sensitive for presence of ESz.
OBJECTIVES: To assess the utility of clinical features in identifying ESz in critically ill patients with alterations of consciousness.
DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective case-control study of 50 patients admitted to the University of North Carolina (UNC) Medical Center and UNC Rex Hospital. Inpatients older than 18 years old undergoing continuous video electroencephalogram (cEEG) were included. Patients admitted for neurologic diagnoses were excluded. A total of 25 patients with ESz (Sz-EEG) were matched with 25 controls by electroencephalogram duration ± 12 hours (No-Sz-EEG). Elements of patient's history and physical findings previously shown to be sensitive for presence of ESz were collected. Descriptive statistical analyses were used.
RESULTS: Most patients were admitted to medical ICUs (72%; n = 36). There was no difference between groups in clinical findings previously shown to be sensitive for ESz. Positive and negative likelihood ratios for these findings generally fell between 1-2 and 0.5-1, respectively, indicating they are inaccurate predictors for ESz. Patients with ESz had significantly higher mortality (p = 0.012).
CONCLUSIONS AND RELEVANCE: Our matched case-control study showed that in the critically ill patient population hospitalized in tertiary care centers and admitted for non-neurologic primary diagnoses, incidence of ocular movement abnormalities, facial/periorbital twitching, and presence of remote risk factors for seizures had low predictive accuracy for ESz. However, these findings are not generalizable to patients with neurologic diseases or to other practice settings with different levels of access to cEEG. We concluded that in this exploratory analysis of hospitalized critically ill patients with non-neurologic diagnoses, these clinical signs did not reliably stratify risk for ESz on cEEG. However, further prospective studies are needed to better evaluate these conclusions.
Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
Heart disease among pregnant women is increasing in incidence. The cardiovascular changes associated with pregnancy may be particularly hazardous for both mother and fetus in a subset of these patients. The period of greatest risk is peripartum while these patients are under the care of the obstetrician and anesthesiologist. Exposing a compromised patient to general anesthesia is further complicated by the cardiovascular stress response to intubation and surgery, the cardiorespiratory implications of mechanical ventilation, the cardiac depression and vasodilation from general anesthetics, residual post-operative respiratory depression from general anesthetics and narcotics and the stress of weaning from mechanical ventilation and post-operative pain.

In the Adult Congenital Heart Program, obstetric patients are followed the by a specialized team of cardiologists, obstetricians and anesthesiologists who also follow all pregnant women referred with acquired cardiac disease. From this referral practice approximately 100 patients per year are now followed during their pregnancy and delivery. In conjunction with the ongoing system we intend to identify all parturients who delivered at the University Health Network (Toronto General Hospital) or Mount Sinai Hospital between the years 1986 and 2001. We will evaluate the anesthetic management of all women with heart disease whose pregnancies were followed at the University Health Network and/or Mount Sinai Hospital between 1986 and 2001.
A total of forty-two (42) subjects with bilateral lower extremity amputations will be enrolled. Subjects will be randomized for assignment into two treatment conditions: twenty-one (21) subjects will use direct observation of another person's foot movements while twenty-one (21) will use mental visualization of foot movements (which will serve as the control group). Subjects in each group will be further be randomized for assignment into six treatment groups: direct observation or mental visualization of right lower extremity movements alone, direct observation or mental visualization of left lower extremity movements alone, or direct observation or mental visualization of simultaneous bilateral lower extremity movements. Subjects will use their assigned therapy for 20 minutes daily. The subjects for this study will be recruited from the Walter Reed Army Medical Center (WRAMC) Amputee clinic. Up to sixty (50) subjects will be recruited and screened according to the inclusion and exclusion criteria since we expect that some may not qualify or drop-out sooner than the scheduled 4-month completion time.
A rapidly evolving field of study suggests a link between the gut microbiome and fecal metabolome with obesity. Recent studies show that environmental exposures, such as ambient air pollution (AAP) exposure can affect gut bacteria and modify risk for obesity. Additionally, proximity to green space has been shown to reduce exposure to air pollutants and increase gut microbial diversity. The investigator's preliminary work has shown that near-roadway air pollution exposure was positively correlated with gut microbial taxa that have been linked with obesity. These findings suggest that air pollution exposure may increase susceptibility to obesity through alterations in the composition and function of the gut microbiome. Despite this, no studies have systematically examined the impact of air pollutants and green space on the gut microbiome and metabolome among adolescents. The overall goal of this research is to determine whether exposure to air pollutants and/or green space affect the gut microbiome and metabolome in young adults residing in Denver, Colorado. This study will examine residential-based estimates of air pollution exposure and green space and also perform detailed gut microbial and metabolite profiling in 100 adolescent and young adults.
<P>PROBLEM TO BE SOLVED: To provide a technique for inhibiting a plasminogen activator inhibitor(PAI) by a plant ingredient that can be taken in as a food.  <P>SOLUTION: The technique comprises using an extract from a plant belonging to Zingiberaceae family such as Curcuma zedoaria ROSC., Crucuma longa L. or Zingiber officinale ROSC. as a PAI-1 inhibitor. In this technique, the plant extract is obtained preferably by removing a polar portions from the hydrous ethanol extract, and among the steps 1 to 3 described below, is obtained preferably by the step 2 or 3: (step 1) The plant body of the above plant is subjected to extraction with a 50-80% ethanol aqueous solution followed by concentration. (step 2) The product obtained by the step 1 is subjected to liquid-liquid extraction with n-hexane and water to obtain a n-hexane phase. (step 3) Ethyl acetate is added to the aqueous phase obtained by the step 2 followed by adding water as desired and then conducting a liquid-liquid extraction to obtain an ethyl acetate phase.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
PCT No. PCT/SE96/00125 Sec. 371 Date Apr. 15, 1996 Sec. 102(e) Date Apr. 15, 1996 PCT Filed Feb. 2, 1996 PCT Pub. No. WO96/24375 PCT Pub. Date Aug. 15, 1996An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antibacterial compounds in a fixed formulation. The fixed formulation is intended for oral use and in the form of an enteric coating layered tablet, an capsule or a multiple unit tableted dosage form. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with Helicobacter infections.
The invention relates to the use of a combination of valproic acid (VPA) and dichloroacetate (DCA) salts (VPA-DCA) in the treatment of cancer. The main anticancer mechanism of action of DCA is inhibition of pyruvate dehydrogenase kinases, inhibition of lactic acid production in cells and blood, and in the case of VPA, inhibition of histone deacetylases, an epigenetic effect on DNA acetylation and methylation. Both investigational medicinal products inhibit aerobic glycolysis, the expression of Na-K-2CI co-transporter RNA in the cell, increase oxidative stress in tumor cells, induce their apoptosis, and suppress cell proliferation. The combination of VPA-DCA reduces serum glucose, sodium and chloride ions in the cell and extracellular space. The pharmacological synergism of the components of this combination inhibits tumor cell proliferation, neoangiogenesis, tumor growth, and invasion. VPA-DCA, as an additional medicinal product may be used to improve the effectiveness of chemotherapy and radiotherapy and to delay tumor resistance.
<P>PROBLEM TO BE SOLVED: To obtain a composition for oral delivery for increasing absorption rate of health food and nutritive substances.  <P>SOLUTION: A delivery system for oral ingestion aiming at absorption improvement includes a food additive such as a surface active agent having melting/absorption improving action, adherent DDS to gastrointestinal mucous membrane having a minute particle body or a three-layered structure and health food/nutritive substances, or as the case may be, a stabilizer and an adhesive. The system is an oral delivery system capable of suppressing separtation/dilution by digestive liquid through holding the health food/nutritive substances with e.g. a surface active agent and delivering to small intestine absorptive cells, and forming high concentration gradient so as to efficiently let the cells absorb. It is effective to add the stabilizer (such as edible protein or a hydrolytic enzyme inhibitor) and the adhesive in the case of expecting to obtain a further higher absorption rate.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1. The exploratory objectives are to evaluate clinical benefit by using Cardio-Microelectromechanical system (CardioMEMS), echocardiography, cardiac magnetic resonance imaging, right heart catheterization, quality of life assessments, and actigraphy to measure changes in clinical response with continued treatment with CS1 in patients with Pulmonary Arterial Hypertension (PAH).

Up to 30 patients are planned for enrollment in the ongoing phase 2 Study CS1-003; thus up to 30 patients could participate in Study CS1-004, if they completed the parent study, tolerated CS1 treatment, and in the investigator's judgement the benefits of continued treatment with CS1 outweigh the risk. Note that as the parent study is ongoing; thus, some patients will directly roll- over into Study CS1-004 with no disruption in CS1 treatment, while other patients that have already completed Study CS1-003, will need to be restarted on CS1. On a yearly basis, the principal investigator will determine if a patient continues the expanded access study for a subsequent year based on safety, tolerability, and clinical benefit of CS1. Continuation of the expanded access study will also be evaluated on a yearly basis by Cereno Scientific (Sponsor).
The research team will provide participants with a pair of shoes to wear throughout the study. The right shoe will be modified to include a 5cm (approximately 2") rocker-style platform which will keep the left leg suspended during walking. Participants will also be provided with a pair of short crutches to assist with walking. Participants in the SA group will sleep for 9 hours for three consecutive nights.
Because Dantrolene Sodium for Injection must be administered at a low concentration in a large volume of fluid, acute toxicity of dantrolene sodium could not be assessed in animals. In 14-day (subacute) studies, the intravenous formulation of dantrolene sodium was relatively non-toxic to rats at doses of 10 mg/kg/day and 20 mg/kg/day. While 10 mg/kg/day in dogs for 14 days evoked little toxicity, 20 mg/kg/day for 14 days caused hepatic changes of questionable biologic significance. 

Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria. 

For acute overdosage, general supportive measures should be employed. 

Intravenous fluids should be administered in fairly large quantities to avert the possibility of crystalluria. An adequate airway should be maintained and artificial resuscitation equipment should be at hand. Electrocardiographic monitoring should be instituted, and the patient carefully observed. The value of dialysis in dantrolene sodium overdose is not known.
PROBLEM TO BE SOLVED: To obtain a skin protective cosmetic usable, without anxiety for anyone who has an oversensitive skin, having good feeling when used and useful as a milky lotion for the skin by including a specific saccharide-bound polymer and a moisture retention ingredient. SOLUTION: This skin protective cosmetic is obtained by including (A) pref. 0.01-10 wt.%, more pref. 0.05-1 wt.%, of a saccharide-bound polymer where group containing, as constituent unit, a saccharide pref. such as glucose is covalent-bound to a polymer base pref. such as an acrylic resin (e.g. a glucosyloxyethyl methacrylate homopolymer), and (B) pref. 0.01-10 wt.%, more pref. 0.05-5 wt.%, of a moisture retention ingredient pref. such as polymethacryloyloxyethyl phosphorylcholine, placenta essence or trehalose.
A series of images of a body part of a user is received. The series of images of the body part of the user are captured over a predetermined time period. A feature of the body part is extracted from the series of images, in which a change in appearance of the extracted feature over the predetermined time period is indicative of a potential health condition of the user. The extracted feature is compared to one or more reference images from a knowledge base to determine a difference between the extracted feature and the one or more reference images. The one or more reference images correlate a particular body feature to a particular potential health condition. A potential health condition of the user is detected based upon the comparing. A notification is sent based upon the detected potential health condition.